DeCure for Immunodeficiency 109 with lymphoproliferation
DeCure's autonomous Immuno AI scientist is researching a drug-repurposing hypothesis for immunodeficiency 109 with lymphoproliferation — screening already-approved drugs against its 1-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleImmunodeficiency 109 with lymphoproliferation maps to a 1-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for immunodeficiency 109 with lymphoproliferation is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
TNF receptor superfamily member 9 (TNFRSF9) — TNFRSF9 is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet apo structuredrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 8GYE · 2.3 Å · ligand none (apo structure). Experimental structure, not a prediction.
What the evidence adds up to
No abstract in this set describes a drug tested specifically for immunodeficiency 109 with lymphoproliferation. The 2017 abstract on HIV-associated lymphoma reports that rituximab plus chemotherapy is feasible and effective for CD20-positive AIDS-related lymphomas, and that combination antiretroviral therapy should be given alongside chemotherapy, but this is a different disease population. The 2007 abstract on common variable immunodeficiency describes genetic defects in molecules such as inducible costimulator, transmembrane activator and calcium-modulator and cytophilin ligand interactor, and CD19, but does not report any drug treatment. The 2013 abstract on X-linked lymphoproliferative diseases outlines diagnostic tools and therapeutic options ranging from prophylactic anti-infective measures to hematopoietic stem cell transplantation and gene therapy, but again provides no drug-specific results. The 2023 abstract on immunodeficiency-associated lymphoproliferative disorders classifies these conditions into four groups — posttransplant, HIV-associated, primary immune disorder-associated, and iatrogenic — but offers no treatment data.
No concrete numbers for survival, response rates, or sample sizes are given in any of these abstracts for immunodeficiency 109 with lymphoproliferation. The results are therefore not disappointing or contradictory; they are simply absent. No drug is mentioned in connection with this specific disease.
What is still missing is any clinical trial data, any drug repurposing evidence, any patient stratification strategy, and any funding directed at this particular immunodeficiency. Without those, no conclusion about treatment can be drawn.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Arthritis Research & Therapy · 2012 · 178 citations · open access
Common variable immunodeficiency - an update
AbstractCommon variable immunodeficiency (CVID) describes a heterogeneous subset of hypogammaglobulinemias of unknown etiology. Typically, patients present with recurrent bacterial infections of the respiratory and gastrointestinal tract. A significant proportion of CVID patients develops additional autoimmune, inflammatory or lymphoproliferative complications. CVID is the most frequent symptomatic primary immunodeficiency encountered in adults. Informative monogenetic defects have been found in single patients and families but in most cases the pathogenesis is still elusive. Numerous immunological studies have demonstrated phenotypic and functional abnormalities of T cells, B cells and antigen-presenting cells. A hallmark is the impaired memory B-cell formation that has been taken advantage of for classifying CVID patients. Clinical multi-center studies have demonstrated a correlation between immunological markers and clinical presentation. Long-term outcome is significantly influenced by delay of diagnosis and treatment and the presence of chronic inflammatory complications. While immunoglobulin replacement therapy plus antibiotics can control infections in most cases, patients with non-infectious inflammatory complications such as granulomatous inflammation, interstitial lung disease, inflammatory bowel disease, lymphoproliferation and developing malignancies still represent a therapeutic challenge. In this review we provide a systematic overview of the immunological, clinical, diagnostic and therapeutic aspects of CVID and highlight recent developments in these fields.
Archives of Internal Medicine · 1991 · 59 citations
Reactive Oxygen Species, Antioxidants, and Acquired Immunodeficiency Syndrome
AbstractA cquired immunodeficiency syndrome (AIDS) results from A infection with a human immunodeficiency virus (HIV-1 or HIV-2) that eventually destroys a specific subset (CD4+) of helper T lymphocytes, so that the patient ultimately succumbs to opportunistic infections and/or certain neoplasms.<sup>1</sup>A high proportion of, and perhaps all, HIV-seropositive patients will show disease progression. Thus, of a cohort of HIV-1—positive subjects who were followed up for 3 years, 19% developed AIDS-related complex (ARC) and 26% developed AIDS.<sup>2</sup>Also, 41% of those who remained asymptomatic showed laboratory evidence of decline of immunologic status.<sup>2</sup>The only drug currently approved for the treatment of AIDS is 3'-azido-3'-deoxythymidine (azidothymidine, or AZT, now called zidovudine), which is therapeutically effective but has significant time- and dose-related toxicity.<sup>3,4</sup> Recent reports have implicated<i>reactive oxygen species</i>both in the pathogenesis of HIV infection and in some of the side effects of drugs such as zidovudine.
Oncology Research and Treatment · 2017 · 38 citations · open access
HIV-Associated Malignant Lymphoma
AbstractAcquired immune deficiency syndrome (AIDS)-related lymphomas (ARL) still represent a relevant field of clinical research. For most histological subtypes of ARL, no optimal initial therapy has been clearly defined so far. Rituximab plus chemotherapy is feasible and effective and should be offered to all patients with CD20-positive ARL regardless of their CD4 cell count. Combination antiretroviral therapy (cART) should be given concomitantly with chemotherapy, bearing in mind potential drug-drug interactions. Appropriate treatment of ARL is determined by a number of factors such as lymphoma stage, performance status, comorbidities, histological subtype, and immunosuppression. Treatment should principally be the same as in human immunodeficiency virus (HIV)-negative lymphoma patients. In HIV-related Hodgkin's lymphoma, high cure rates have been achieved with stage-adapted treatment approaches, albeit with worse outcomes compared to immunocompetent patients.
International Journal of Immunogenetics · 2007 · 31 citations · open access
Genetic defects in common variable immunodeficiency
AbstractCommon variable immunodeficiency (CVID) is the most frequent clinically manifested primary immunodeficiency. According to clinical and laboratory findings, CVID is a heterogeneous group of diseases. Recently, the defects of molecules regulating activation and terminal differentiation of B lymphocytes have been described in some patients with CVID. In this study, we show the overview of deficiencies of inducible costimulator, transmembrane activator and calcium-modulator and cytophilin ligand interactor, CD19 molecules, their genetic basis, pathogenesis and clinical manifestations.
Lymphoproliferative Disorders in Immunocompromised Individuals and Therapeutic Antibodies for Treatment
AbstractThe incidence of lymphoproliferative disease (LPD) is significantly higher in individuals who have congenital, acquired or iatrogenically induced immunodeficiency. Although there are a wide range of LPDs including lymphoma and leukemia, this article only covers LPDs in patients with impaired immune function, which are called immunodeficiency-associated LPDs (ID-LPDs). Three of the four ID-LPD categories recognized by WHO have been selected for discussion: LPD in primary immune disorders, post-transplant LPD and LPD in HIV infection. Because of the high incidence and mortality of ID-LPDs, careful evaluation of the morphology, immunophenotype, genotype, viral status and clinical history is required for accurate diagnosis and treatment. Recently, treatment with monoclonal antibodies (mAbs) has been widely used and developed because of its potential benefits. The aim of this review is to describe new information concerning mAb treatment in LPDs and to draw physicians' attention to mAb therapy, which should be effective for some types of LPD.
Granulomatous Lymphocyte Interstitial Lung Disease: A Rare Complication of Common Variable Immunodeficiency Managed With Azathioprine and Rituximab
AbstractGranulomatous lymphocytic interstitial lung disease (GL-ILD) is a rare, non-infectious pulmonary manifestation of common variable immunodeficiency (CVID). Diagnosing and managing GLILD remains challenging due to its poorly understood pathogenesis and high mortality. We present a complex case of a young female with CVID associated with lung and spinal cord involvement managed with azathioprine and rituximab.
Oxford University Press eBooks · 2013 · 0 citations
X-Linked Lymphoproliferative Diseases
AbstractAbstract Primary immunodeficiency diseases are inherited disorders that affect human adaptive and innate immunity. In most cases, affected individuals experience recurrent infections, but they may also suffer from autoimmune diseases and malignancies. This chapter focuses on X-Linked Lymphoproliferative Diseases,including the historic and scientific background, clinical presentations, immunologic characteristics, and the molecular/genetic underpinnings. Where appropriate, diagnostic tools and therapeutic options are outlined -- from prophylactic anti-infective measures to hematopoietic stem cell transplantation and gene therapy.
AbstractImmunodeficiency-associated lymphoproliferative disorders (IA-LPDs) encompass a heterogeneous group of disorders that stem from diverse clinical settings and underlying disorders. These disorders may be benign lymphoproliferations to aggressive lymphomas. The World Health Organization (WHO) broadly classifies IA-LPDs into four groups: posttransplant lymphoproliferative disorders (PTLDs), lymphomas associated with HIV, lymphoproliferations associated with primary immune disorders, and other iatrogenic lymphoproliferative disorders. This chapter focuses on IA-LPDs of primary immune deficiencies seen commonly in the pediatric population, HIV-associated lymphoma, and iatrogenic lymphoproliferations.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
